Sports performance research ↗ · Military & occupational performance ↗
OCCUPATIONAL MEDICINE / SOURCE RECORDSGazprom peptide research.
Occupational studies of Gazprom workers in the Russian Far North, including tissue-peptide programs and measures of adaptation to the work environment.
Findings from selected studies
- Sick leave among 113 workers
During an individually assigned, multi-preparation program, days unfit for work fell from 119 to 60 compared with the preceding year. There was no concurrent control group, and the difference in seasonal illness was inconclusive.
Browse study findings by subject ↓
The 113-worker Urengoy report
The original 2016 paper records 18 → 10 sick-leave certificates and 119 → 60 days unfit for work in 2014 versus 2015. Seasonal morbidity did not improve reliably. This was a historical comparison of a personalized program, with no concurrent control.
The paper names Endoluten, Vesugen, Crystagen, Pinealon and Cartalax; Cerluten also appears in the risk-based assignments. These are shared program results, not separate product effects. Its narrative 43.4% reduction does not match the table’s 119 → 60 days.
Personified prevention of diseases under the conditions of the Far North
Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments · Journal publication
S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · Vrach. 2016;(6):64–66
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
Results and tables
Reported findings and study design
A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Population or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Dose, route and schedule
One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.
Protocol source ↗ · Original PDF p.65
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sick-leave certificates | 18 → 10 | 2014 → 2015; whole program |
| Days unfit for work | 119 → 60 | 2014 → 2015; whole program |
| Seasonal morbidity | No statistically reliable improvement reported | |
| Narrative/table discrepancy | Narrative 43.4% decrease; Table 2 gives 119 → 60 days | Unresolved source discrepancy; not interchangeable figures |
Table 2 · Chronic-disease recurrence-related sick leave
| Measure | 2014 | 2015 |
|---|---|---|
| Sick-leave certificates | 18 | 10 |
| Days unfit for work | 119 | 60 |
Historical comparison for the shared 113-worker program. Not preparation-specific results.
One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
- Source reviewed
- Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
- One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.
Reviewed 2026-11-01.
What can the other sources establish?
The congress citation, program narrative and dissertation are different documents. They should not be counted as three independent trials. The complete protocol and dissertation are needed to verify preparations, comparison groups and participant numbers for each outcome.
Which peptides were involved?
The dissertation excerpts name Thymalin, Epithalamin and Cortexin in sequential treatment for dyscirculatory encephalopathy. That does not establish what every program participant received. These tissue-derived preparations are distinct from synthetic Vilon, Epitalon, Pinealon and Vesugen.
Reported outcomes need their original tables
The reproduced narrative reports HDL +35%, VLDL -53% and LDL -30%; ultrasound improvement in thyroid, prostate and liver subgroups is reported as 61%, 41% and 35%. Follow-up imaging is described at approximately four, eight and twelve months. These findings require subgroup denominators, baseline data and control comparisons. Imaging changes do not independently demonstrate tissue regeneration.
Read the reproduced program narrative ↗
Core source records
Program of Age-Related Pathology Prevention and Professional Longevity Extension among Gazprom Personnel
· Conference citation in author bibliography
R. I. Vyakhirev, N. N. Gouslisty, S. V. Okhotnikov, V. Kh. Khavinson · 17th World Congress of the International Association of Gerontology; Gerontology 47(Suppl. 1):453-454
The author bibliography lists a Vancouver congress abstract in Gerontology 47, Supplement 1, pages 453-454. This confirms a publication trail, not clinical efficacy.
- Population / setting
- Gazprom personnel; abstract-level participant details unavailable
- Source reviewed
- Author bibliography checked; abstract text not obtained.
Study limitations
- Conference abstract and original protocol not recovered.
- A bibliographic listing does not verify intervention identity, allocation or outcomes.
Reviewed 2026-10-02.
Программа продления активного профессионального долголетия работников ОАО «Газпром» — Program for extending active professional longevity of Gazprom employees
Individualized bioregulating interventions; exact formulations unresolved · Program report / commercial reproduction
· Program narrative reproduced by Vitual; publication date unconfirmed
The reproduced report describes 11,192 employees reached during March-November 2000. It claims 2.3-fold lower overall morbidity and 2.7-fold lower seasonal infectious morbidity. These are report-level claims, not independently established treatment effects.
- Population / setting
- Gazprom occupational program; analyzed subgroups and denominators unresolved
- Source reviewed
- Accessible Russian narrative checked. Image-based tables and original program documentation require independent appraisal.
Study limitations
- Commercial reproduction; original signed report and underlying data not obtained.
- Outcome-specific denominators, allocation, confounding, adverse events and exact formulations need verification.
- Program reach is not the number contributing to every outcome; no modern synthetic peptide inherits these results.
Reviewed 2026-10-02.
Эффективность применения пептидных биорегуляторов у лиц разного возраста в условиях Крайнего Севера — Effectiveness of peptide bioregulators in people of different ages under Far North conditions
Thymalin, Epithalamin and Cortexin tissue-derived preparations · Dissertation record and indexed excerpts
Vladimir Alekseevich Cherkashin · Candidate of Medical Sciences dissertation, St. Petersburg, 2003; 203 pages
The dissertation trail links examinations of Gazprom employees and family members to the program approved in February 2000. Indexed recommendations name sequential Thymalin, Epithalamin and Cortexin for a disease-specific setting; they do not establish a universal occupational regimen.
- Population / setting
- Far North clinical research associated with Gazprom employees and families; exact cohort allocation unresolved
- Source reviewed
- Available sources include bibliographic metadata and dissertation excerpts. The complete thesis was unavailable for review.
Study limitations
- Full 203-page dissertation has not been obtained.
- Search-indexed excerpts are not a substitute for original methods and tables.
- Named sequential therapy for dyscirculatory encephalopathy does not identify treatment for every Gazprom employee.
- Overlap with the broader program and other clinical cohorts remains unresolved.
Reviewed 2026-10-02.
Dissertation and bibliography priorities
Cherkashin: complete dissertation · 2002 thymus/pineal monograph · 2001 aging monograph lead
Priority sections are participant selection, treatment identity, allocation, adverse events, original outcome tables and the bibliography. A commercial acquisition listing is not a verified PDF download.
Northern occupational physiology
Krivoshonov and Okhotnikov (2000), Production Migration and Human Health in the North. Full publication details remain uncertain.
Cerebral circulation
Krivoshapkin (1993) cerebral-ischemia work and the Epithalamin/Cortexin traumatic-brain-injury dissertation are related acquisition leads, not Gazprom trial results.
Experimental toxicity
The 2004 Lebnikova/Zhamsaranova 2,4-D herbicide paper requires primary-paper retrieval. It cannot establish benzene or hydrogen-sulfide protection.
Cold-stress research
Arokina and colleagues (2022) describe a vascular polypeptide complex in rats. The formulation and its relationship to Vesugen remain unclear.
Modern Arctic occupational health
The Gazprom Dobycha Yamburg cardiovascular-risk dissertation concerns occupational risk; it is not automatically a peptide intervention study.
Cohort overlap
Compare the dissertation, conference abstract, program narrative and long-term gerontology publications. Shared authors or similar treatments neither prove independence nor prove shared participants.
Reporting discrepancies
Secondary accounts describe different sample totals, controls, durations and preparations. Original protocols and independent corroboration are needed before reconciling these versions or publishing mortality claims.
Study findings by subject
2 source records
2001 · Research record
Program of Age-Related Pathology Prevention and Professional Longevity Extension among Gazprom Personnel
The author bibliography lists a Vancouver congress abstract in Gerontology 47, Supplement 1, pages 453-454. This confirms a publication trail, not clinical efficacy.
Observational study
Программа продления активного профессионального долголетия работников ОАО «Газпром» — Program for extending active professional longevity of Gazprom employees
The reproduced report describes 11,192 employees reached during March-November 2000. It claims 2.3-fold lower overall morbidity and 2.7-fold lower seasonal infectious morbidity. These are report-level claims, not independently established treatment effects.